Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.
about
T Cells: Soldiers and Spies--The Surveillance and Control of Effector T Cells by Regulatory T CellsOral tolerance to food proteinThe Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical OverviewImmune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationRetinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cellsIntravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD.Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acidUnique properties of thymic antigen-presenting cells promote epigenetic imprinting of alloantigen-specific regulatory T cells.SOCS1 and regulation of regulatory T cells plasticity.Chimeric antigen receptors for T cell immunotherapy: current understanding and future directionsShift of graft-versus-host-disease target organ tropism by dietary vitamin A.Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Optimal isolation of functional Foxp3+ induced regulatory T cells using DEREG mice.Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host diseaseAntigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance.Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice.HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host DiseaseComparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and ButyrateCell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.Regulatory T Cells Resist Cyclosporine-Induced Cell Death via CD44-Mediated Signaling Pathways.IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localizationInduced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?Polyclonal CD4+Foxp3+ Treg cells induce TGFβ-dependent tolerogenic dendritic cells that suppress the murine lupus-like syndrome.TGF-β-Induced Regulatory T Cells Directly Suppress B Cell Responses through a Noncytotoxic MechanismRegulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive?CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in micePeripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and functionRegulatory T-Cell Therapy for Graft-versus-host Disease.Treatment of graft-versus-host disease with naturally occurring T regulatory cells.Prevention of allogeneic cardiac graft rejection by transfer of ex vivo expanded antigen-specific regulatory T-cells.Regulatory T cells for the prevention of graft-versus-host disease: professionals defeat amateurs.Regulatory T cells and IL-17-producing cells in graft-versus-host disease.Clinical perspectives for regulatory T cells in transplantation tolerance.Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation.The role of regulatory T cells in the biology of graft versus host disease.Potential and limitations of regulatory T-cell therapy in solid organ transplantation.Intestinal mucosal tolerance and impact of gut microbiota to mucosal toleranceThe potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy
P2860
Q26823613-F67E5E03-7BE6-47BA-9A9C-983D1B904035Q27026259-A7B67F42-BB06-4347-AEDF-6A148CA55453Q28066083-6A798FAD-C506-40D5-BBAC-97AF5984F355Q28072627-55C8548A-117A-4B3C-B752-0AB3D3A32580Q28743652-A61E5AEF-3881-445E-85B3-0102CF4A6C5FQ30573584-67DFDC58-CB88-4E66-B48F-66BBB74482CEQ33778359-0EB57916-A3C5-4AA7-BFD3-BB90EB92E5EBQ33829220-5DC83BC0-B4A1-421F-A527-A54C523E53F6Q34009286-73015280-0EA1-4AEF-B18B-80641B57DBB4Q34248531-CE288FA6-57AD-49F0-B878-7FFD43CF855CQ34292981-C19F2E7E-1558-4624-9A65-27105569A501Q34293038-D82119A7-B40C-4A37-9087-958227E7F0CEQ34408309-4A358F8F-A44E-49F1-AF17-B6822B530B46Q35053246-52D3186B-1D68-49C6-B8DD-F303FF8D421FQ35190507-5B91588C-1C9B-43F2-95FC-33BF789225E3Q35669076-EA2889AD-B27A-4968-B57A-395FD94B435EQ35815893-286945CC-D823-4A25-89FC-8609FC683479Q35926395-5F92D466-5598-453E-A3A8-FA965231F971Q36015241-D2B7CDAE-51B5-4D45-95C2-475C247CD788Q36089251-10BEADED-1260-4070-9BA0-E337B1A13041Q36200557-19B58114-B788-45C8-A074-614929967481Q36378864-87405EF6-E8D3-45F0-B3C1-9041A387DDE3Q36470364-B6DA8854-154C-4F44-B677-C964843702DAQ36905992-FA0084F3-1B93-44FB-B87F-16CC29E2B5BBQ37021703-5D609D5D-0360-4AB9-B2F0-9E1BD34E3F46Q37079114-E771CA5D-D4F6-4D1B-A136-1A0C7A25B50AQ37122171-5678D043-E530-47E8-99A1-39954C2EE8C6Q37309438-02D6347E-FA70-4C7D-88BA-E4E3F1546235Q37321716-A528128E-72B9-4A94-A0A3-1756D4492B6EQ37548930-C1BE2C0F-A99D-4433-AC0B-EBBD93F6105EQ37624578-B72E0737-C77D-42BB-B81D-792D65AF83A6Q37900645-A43BEF57-CBB8-484F-AAD3-48B6B0387291Q37912653-B123D566-9C55-40D9-95AA-29595A94AE2AQ38000048-19D7F03E-48D0-4E16-8E3A-25C579DD8A0EQ38095964-B6AAB102-A885-4F32-9BFD-921DE07988EBQ38117369-56711FE0-B2AC-4B69-AD8E-BD972D36D6A2Q38235166-403A2921-E429-482D-9619-E4D29A9304CFQ38335183-AAC310E0-0E64-4D32-9890-550859BA72F0Q39012031-E89CA55A-FB89-43AC-9B9C-1502D07B4970Q39559727-E93506D8-A513-483D-B6D1-7AFCABF27707
P2860
Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Alloantigen-specific de novo-i ...... rotect from experimental GVHD.
@en
Alloantigen-specific de novo-i ...... rotect from experimental GVHD.
@nl
type
label
Alloantigen-specific de novo-i ...... rotect from experimental GVHD.
@en
Alloantigen-specific de novo-i ...... rotect from experimental GVHD.
@nl
prefLabel
Alloantigen-specific de novo-i ...... rotect from experimental GVHD.
@en
Alloantigen-specific de novo-i ...... rotect from experimental GVHD.
@nl
P2093
P2860
P50
P356
P1476
Alloantigen-specific de novo-i ...... protect from experimental GVHD
@en
P2093
Anja Bubke
Arnold Ganser
Jochen Huehn
Niklas Czeloth
Susanne Schmitz
P2860
P304
P356
10.1002/EJI.200939432
P407
P577
2009-11-01T00:00:00Z